<DOC>
	<DOC>NCT01302002</DOC>
	<brief_summary>The study will test metformin in patients with early breast cancer. Blood and tissue will be collected before and after the use of metformin.</brief_summary>
	<brief_title>The Use of Metformin in Early Breast Cancer Patients Pre-Surgery</brief_title>
	<detailed_description>Patients will take metformin twice a day for 3 weeks before surgery. The hypothesis is that metformin will reduce cell proliferation rates (Ki67) and increase apoptoses (TUNEL)in tumor tissue. The study will collect and analyze pre- and post-treatment blood specimens for: - Serum glucose - Insulin levels - Estradiol - HOMA test - Glycosylated haemoglobin</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Invasive breast cancer T1 or T2, Nx Knowledge of the investigational nature of the study and ability to provide consent for study participation Diabetes or baseline glucose or Glycosylated haemoglobin upper limit of normal for the institution Recent use of corticosteroids AST &gt; 1.5 times upper limit of normal for the institution Pregnancy Serious clinical illness Prior or concurrent systemic neoadjuvant Breast Cancer therapy.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metformin</keyword>
	<keyword>Pre-Surgery</keyword>
</DOC>